BioNxt Solutions (OTCMKTS:BNXTF) and Journey Medical (NASDAQ:DERM) Head to Head Comparison

Journey Medical (NASDAQ:DERM) and BioNxt Solutions (OTCMKTS:BNXTF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Volatility and Risk

Journey Medical has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, BioNxt Solutions has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Institutional & Insider Ownership

7.3% of Journey Medical shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Journey Medical and BioNxt Solutions”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86 million	2.77	-$11.43 million	($0.37)	-16.81
BioNxt Solutions	$20,000.00	1,531.13	-$5.43 million	($0.05)	-5.00

BioNxt Solutions has lower revenue, but higher earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than BioNxt Solutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Journey Medical and BioNxt Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
BioNxt Solutions	N/A	N/A	-879.46%

Analyst Ratings

This is a breakdown of current ratings and price targets for Journey Medical and BioNxt Solutions, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1	1	2	0	2.25
BioNxt Solutions	0	0	0	0	0.00

Journey Medical currently has a consensus target price of $13.00, suggesting a potential upside of 109.00%. Given Journey Medical’s stronger consensus rating and higher possible upside, equities analysts clearly believe Journey Medical is more favorable than BioNxt Solutions.

Summary

Journey Medical beats BioNxt Solutions on 8 of the 14 factors compared between the two stocks.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.